6 ms·
It's not just America, there's a case in the EU right now where a company for some reason as gotten a 10 year exclusive on a drug that cost basically nothing. I
by mrweasel 10y ago
It's not just America, there's a case in the EU right now where a company for some reason as gotten a 10 year exclusive on a drug that cost basically nothing. It has now gone up 4000% in price. This is for an out of patent drug.
That company for some reason got an exclusive, by using a law that was suppose to ensure that companies could recoup development cost. In this case it's a drug that pharmacies used to make, there's absolutely NO COST to recoup.
- willvarfar 10y agoGot any links, or name of the drug?
- mrweasel 10y agoSure, it's Caffeine Citrate: https://en.wikipedia.org/wiki/Caffeine_citrate https://en.wikipedia.org/wiki/Caffeine_citrate it's now being sold under the brand Peyona, by a company called Chiesi. If you feel like learning Danish: http://www.dr.dk/nyheder/indland/fra-en-20er-til-800-kroner-medicinalfirma-haever-prisen-paa-livsvigtig-medicin-til http://www.dr.dk/nyheder/indland/fra-en-20er-til-800-kroner-... Basically the price has jumped from 3.33USD to 121USD.
- replicatorblog 10y agoThis also happens in the case of Shkreli-types. Part of the problem is that the market size for the drugs tend to be small, but the R&D and regulatory costs are high enough to keep out competitors so you have these "orphan drug" companies able to jack up prices even in the absence of patent protection.